An optimized enzyme-linked lectin assay to measure influenza A virus neuraminidase inhibition antibody titers in human sera.
about
Influenza virus neuraminidase (NA): a target for antivirals and vaccines.Comparative Efficacy of Monoclonal Antibodies That Bind to Different Epitopes of the 2009 Pandemic H1N1 Influenza Virus Neuraminidase.Hemagglutinin Stalk- and Neuraminidase-Specific Monoclonal Antibodies Protect against Lethal H10N8 Influenza Virus Infection in MiceComparability of neuraminidase inhibition antibody titers measured by enzyme-linked lectin assay (ELLA) for the analysis of influenza vaccine immunogenicityInfluenza Neuraminidase Subtype N1: Immunobiological Properties and Functional Assays for Specific Antibody Response.Analysis of Anti-Influenza Virus Neuraminidase Antibodies in Children, Adults, and the Elderly by ELISA and Enzyme Inhibition: Evidence for Original Antigenic Sin.An influenza A virus (H7N9) anti-neuraminidase monoclonal antibody with prophylactic and therapeutic activity in vivo.Workshop report: Immunoassay standardisation for "universal" influenza vaccines.Surveillance Study of Influenza Occurrence and Immunity in a Wisconsin Cohort During the 2009 PandemicStructural characterization of a protective epitope spanning A(H1N1)pdm09 influenza virus neuraminidase monomers.Optimization of an enzyme-linked lectin assay suitable for rapid antigenic characterization of the neuraminidase of human influenza A(H3N2) viruses.Persistence of Antibodies to Influenza Hemagglutinin and Neuraminidase Following One or Two Years of Influenza Vaccination.Neuraminidase-based recombinant virus-like particles protect against lethal avian influenza A(H5N1) virus infection in ferrets.Antibody Responses to Trivalent Inactivated Influenza Vaccine in Health Care Personnel Previously Vaccinated and Vaccinated for The First Time.Molecular characterization of neuraminidase genes of influenza A(H3N2) viruses circulating in Southwest India from 2009 to 2013.Immunobiological properties of influenza A (H7N9) hemagglutinin and neuraminidase proteins.Correlates of Protection against Influenza in the Elderly: Results from an Influenza Vaccine Efficacy Trial.Modest Waning of Influenza Vaccine Efficacy and Antibody Titers During the 2007-2008 Influenza Season.An influenza A virus (H7N9) anti-neuraminidase monoclonal antibody protects mice from morbidity without interfering with the development of protective immunity to subsequent homologous challenge.Influenza A virus hemagglutinin specific antibodies interfere with virion neuraminidase activity via two distinct mechanisms.Measuring Influenza Neuraminidase Inhibition Antibody Titers by Enzyme-linked Lectin Assay.Antibody to Influenza Virus Neuraminidase: An Independent Correlate of Protection.An H10N8 influenza virus vaccine strain and mouse challenge model based on the human isolate A/Jiangxi-Donghu/346/13.Influenza Virus Hemagglutinin Stalk-Specific Antibodies in Human Serum are a Surrogate Marker for In Vivo Protection in a Serum Transfer Mouse Challenge ModelKinetics, longevity and cross-reactivity of anti-neuraminidase antibody after natural infection with influenza A viruses.The Household Influenza Vaccine Effectiveness Study: Lack of Antibody Response and Protection Following Receipt of 2014-2015 Influenza Vaccine.Comparison of the Efficacy of N9 Neuraminidase-specific Monoclonal Antibodies against Influenza A(H7N9) Virus Infection.Antigenicity of the 2015-2016 seasonal H1N1 human influenza virus HA and NA proteins.Towards the electrochemical diagnostic of influenza virus: development of a graphene-Au hybrid nanocomposite modified influenza virus biosensor based on neuraminidase activity.H5N1 influenza vaccine induces a less robust neutralizing antibody response than seasonal trivalent and H7N9 influenza vaccines.Antibodies directed towards neuraminidase N1 control disease in a mouse model of influenza.Integrase Defective Lentiviral Vector as a Vaccine Platform for Delivering Influenza Antigens.Influenza A(H7N9) Virus Antibody Responses in Survivors 1 Year after Infection, China, 2017.Neuraminidase: Another Piece of the Influenza Vaccine Puzzle.NAction! How Can Neuraminidase-Based Immunity Contribute to Better Influenza Virus Vaccines?Epidemiological Studies to Support the Development of Next Generation Influenza Vaccines.Neuraminidase-Inhibiting Antibody Titers Correlate with Protection from Heterologous Influenza Virus Strains of the Same Neuraminidase SubtypeNeuraminidase as an influenza vaccine antigen: a low hanging fruit, ready for picking to improve vaccine effectivenessComparison of Adjuvanted-Whole Inactivated Virus and Live-Attenuated Virus Vaccines against Challenge with Contemporary, Antigenically Distinct H3N2 Influenza A Viruses
P2860
Q30249879-1F60D0D8-A1F2-4A13-BC16-6CD246754256Q30380287-501741C3-C692-4708-9024-8600B7DDED55Q30380785-2635CA88-0098-4F1E-9EF8-7E1842D17C7AQ30382921-2E7D7025-B503-4171-BF81-D65A2C63D01FQ30386612-8CFE23B5-8BBB-4E6C-B796-179ADF4F694BQ30400179-E03CF91F-6CE7-4137-8302-F18DBD7EAE33Q30571702-B2A74048-08C7-49DD-B5A8-1596B3105EA1Q33619871-7A358AAD-DA53-459E-843A-9F3A5BA4D8C9Q33904286-539C3E4D-75A8-4B56-A03D-A2465E4B37A5Q35139986-3A0BA99E-E843-4063-81A0-A7DA48369218Q35235777-2C60BDF9-0F2D-4D1E-A624-C11BABBB00E6Q36306922-1300149B-8D68-4404-A01A-01247B80EE3AQ36408162-E1B9C8F2-BE4F-4A64-BD33-3B40C45A02A8Q37591325-FFAD8936-34E9-4941-8F7D-F5F599A92A4AQ38375680-EC878222-46C1-4CD3-9875-29BDDFAA4E5EQ38758513-F74214C7-31B6-449A-9030-D63FC279E00AQ38852557-187C38C9-F2FA-4BC8-A992-6D5A60DAFF93Q39837983-FEDD1CA7-8771-4237-AD4A-E8E00472977FQ40049822-A8B24ACC-1F7C-44A3-85F6-7548EC0FE764Q40459715-B11E7B13-DB40-4EB6-A5EC-5B640C78CFA3Q40523208-89BFAFD6-BE81-4D8E-AE09-16AA0028DF2DQ41347626-41F3C3A7-4561-497A-83AB-F5A3CD0C86D9Q41531938-698F7426-2308-4301-8A58-F7C8EEE67EABQ41676246-E03BC8CF-1400-4E98-B1A9-979B1596FB78Q41918783-B180CD94-2A70-4479-B0E9-C998450BB498Q41919202-24299761-16AB-453E-82DC-32E6EE8AD9E1Q45324380-DE4C3808-3591-4BEB-B0CA-495321DE6C51Q45324745-E18E3E5E-35B0-4260-9D8F-5861B7A372AFQ45324883-D54B6C30-682E-4CD8-B4D2-B04CEBDEB43BQ47149344-A8637306-06E0-4E3C-940E-F25A8827EF07Q47426452-6A81E7AA-9806-40D4-8A17-1D9096BA8B3BQ49829189-14E3B299-AE71-4F5A-BE44-62DA9731D984Q50064174-6044F770-53D3-4795-8D11-8B688BF57C94Q51034194-6339673E-598F-4FCA-9DB4-01CBE35632B6Q52609074-3EBD0E1C-1E17-4917-9DE6-B6D01D55A6E5Q52627557-DA783220-81F1-41B8-B9E0-34DBEB62FE93Q57093905-5F9B13CC-4800-4BFA-8060-8266F2E41397Q57094018-2F98F8F0-90E1-4E1D-8B66-23CBE858A045Q58706119-06BCE1C1-C2A7-4516-9D08-CC4BF17F52A3
P2860
An optimized enzyme-linked lectin assay to measure influenza A virus neuraminidase inhibition antibody titers in human sera.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
An optimized enzyme-linked lec ...... antibody titers in human sera.
@en
An optimized enzyme-linked lec ...... antibody titers in human sera.
@nl
type
label
An optimized enzyme-linked lec ...... antibody titers in human sera.
@en
An optimized enzyme-linked lec ...... antibody titers in human sera.
@nl
prefLabel
An optimized enzyme-linked lec ...... antibody titers in human sera.
@en
An optimized enzyme-linked lec ...... antibody titers in human sera.
@nl
P2093
P50
P1476
An optimized enzyme-linked lec ...... antibody titers in human sera.
@en
P2093
Kim Westgeest
Laura Couzens
Vladimir Lugovtsev
P356
10.1016/J.JVIROMET.2014.09.003
P577
2014-09-16T00:00:00Z